Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells

Current Medicinal Chemistry

Volumn 20, Issue 19, 2013, Pages 2467-2475

  Scotece, M ^a   Gomez R ^a   Conde, J ^a   Lopez, V ^a   Gomez Reino J J ^a   Lago, F ^b   Smith, A B ^c   Gualillo, O ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Chemokines; Multiple myeloma; Natural drugs; Nutraceuticals; Oleocanthal; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEOCANTHAL; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ALDEHYDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL3; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MULTIPLE MYELOMA; PHENOLS; PLANT OILS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84877952121     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320190006     Document Type: Article

References (28)

1. Ocio E.M.; Maiso, P.; Chen, X.; Garayoa, M.; Alvarez-Fernández, S.; San-Segundo, L.; Vilanova, D.; López-Corral, L.; Montero, J.C.; Hernández-Iglesias, T.; de Alava, E.; Galmarini, C.; Avilés, P.; Cuevas, C.; San-Miguel, J.F.; Pandiella, A. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA doublestrand breaks. Blood, 2009, 113, 3781-3791.
2. Kagoya, Y.; Nannya, Y.; Kurokawa, M. Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis. Leuk. Res., 36 (8), 1016-1021.
3. Zangari, M.; Terpos, E.; Zhan, F.; Tricot, G. Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treat. Rev., in press, doi:10.1016/j.ctrv.2011.12.007.
4. Cives, M.; Milano, A.; Dammacco, F.; Silvestris, F. Lenalidomide in multiple myeloma: current experimental and clinical data. Eur. J. Haematol., 2012, 88, 279-291.
5. Ferrarin, M.; Ferrero, E.; Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. Curr. Med. Chem., 2011, 18 (34), 5185-5195.
6. Rödel, F.; Reichert, S.; Sprenger, T.; Gaipl, U.S.; Mirsch, J.; Liersch, T.; Fulda, S.; Rödel, C. The role of Survivin for Radiation Oncology: Moving Beyon Apoptosis Inhibition. Curr. Med. Chem., 2011, 8, 191-199.
7. Ogata, A.; Anderson, K.C. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Leuk. Res., 1996, 20, 303-307. (Pubitemid 26168268)
8. Ogata, A.; Chauhan, D.; Urashima, M.; Teoh, G.; Treon, S.P.; Anderson, K. C. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin. Cancer Res., 1997, 3, 1017-1022. (Pubitemid 27253011)
9. Tsubaki, M.; Kato, C.; Manno, M.; Ogaki, M.; Satou, T.; Itoh, T.; Kusunoki, T.; Tanimori, Y.; Fujiwara, K.; Matsuoka, H.; Nishida, S. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol. Cell Biochem., 2007, 304, 53-60. (Pubitemid 47456852)
10. Lentzsch, S.; Gries, M.; Janz, M.; Bargou, R.; Dörken, B.; Mapara, M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood, 2003, 101, 3568-3573. (Pubitemid 36857943)
11. Kukita, T.; Nomiyama, H.; Ohmoto, Y.; Kukita, A.; Shuto, T.; Hotokebuchi, T.; Sugioka, Y.; Miura, R.; Iijima, T. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest., 1997, 76, 399-406. (Pubitemid 27157347)
12. Fuller, K.; Owens, J.M.; Chambers, T.J. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J. Immunol., 1995, 154, 6065-6072.
13. Choi, S.J.; Cruz, J.C.; Craig, F.; Chung, H.; Devlin, R.D.; Roodman, G.D.; Alsina, M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood, 2000, 96, 671-675. (Pubitemid 30463390)
14. Colomer, R.; Menéndez, J.A. Mediterranean diet, olive oil and cancer. Clin. Transl. Oncol., 2006, 8, 15-21.
15. Han, J.; Talorete, T.P.; Yamada, P.; Isoda, H. Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology, 2009, 59, 45-53.
16. Owen, R.W.; Mier, W.; Giacosa, A.; Hull, W.E.; Spiegelhalder, B.; Bartsch, H. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignansand squalene. Food Chem. Toxicol., 2000, 38, 647-659. (Pubitemid 30447459)
17. Gill, C.I.; Boyd, A.; McDermott, E.; McCann, M.; Servili, M.; Selvaggini, R.; Taticchi, A.; Esposto, S.; Montedoro, G.; McGlynn, H.; Rowland, I. Potential anti-cancer effects of virgin olive oil phenols on colorectal carcinogenesis models in vitro. Int. J. Cancer, 2005, 117, 1-7. (Pubitemid 41262753)
18. Beauchamp, G.K.; Keast, R.S.; Morel, D.; Lin, J.; Pika, J.; Han, Q.; Lee, C.H.; Smith, A.B.; Breslin, P.A. Phytochemistry: ibuprofenlike activity in extra-virgin olive oil. Nature, 2005, 437, 45-46. (Pubitemid 41613421)
19. Pitt, J.; Roth, W.; Lacor, P.; Smith, A.B. 3rd, Blankenship, M.; Velasco, P.; De Felice, F.; Breslin, P.; Klein, W.L. Alzheimer'sassociated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol. Appl. Pharmacol., 2009, 240, 189-197.
20. Iacono, A.; Gómez, R.; Sperry, J.; Conde, J.; Bianco, G.; Meli, R.; Gómez-Reino, J.J.; Smith, A.B. 3rd; Gualillo, O. Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. Arthritis Rheum., 2010, 62, 1675-1682.
21. Scotece, M.; Gómez, R.; Conde, J.; Lopez, V.; Gómez-Reino, J.J.; Lago, F.; Smith, A.B., 3rd.; Gualillo, O. Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1 and IL-6 in J774 macrophages and in ATDC5 chondrocytes. Life Sci., 2012, 91 (23-24), 1229-1235.
22. Silva, M.T.; do Vale, A.; dos Santos, N.M. Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis., 2008, 13 (4), 463-482.
23. Vallet, S.; Pozzi, S.; Patel, K.; Vaghela, N.; Fulciniti, M.T.; Veiby, P.; Hideshima, T.; Santo, L.; Cirstea, D.; Scadden, D.T.; Anderson, K.C.; Raje, N. A novel role for CCL3 (MIP-1alpha) in myelomainduced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia, 2011, 25, 1174-1181.
24. Hsu, J.; Shi, Y.; Krajewski, S.; Renner, S.; Fisher, M.; Reed, J.C.; Franke, T.F.; Lichtenstein, A. The AKT kinase is activated in multiple myeloma tumor cells. Blood, 2001, 98, 2853-2855.
25. Berenson, J.R.; Ma, H.M.; Vescio, R. The role of nuclear factorkappaB in the biology and treatment of multiple myeloma. Semin. Oncol., 2001, 28, 626-633. (Pubitemid 33138161)
26. Bharti, A.C.; Donato, N.; Singh, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 2003, 101, 1053-1062. (Pubitemid 36139379)
27. Giuliani, N.; Lunghi, P.; Morandi, F.; Colla, S.; Bonomini, S.; Hojden, M.; Rizzoli, V.; Bonati, A. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia, 2004, 18, 628-635. (Pubitemid 38425880)
28. Catlett-Falcone, R.; Landowski, T.H.; Oshiro, M.M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernández-Luna, J.L.; Nuñez, G.; Dalton, W.S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10, 105-115. (Pubitemid 29077388)